Skip to Main Content

The experimental drug known as aducanumab has long been seen as the next big hope on the horizon for Alzheimer’s patients — but that hope came crashing down on Thursday, when developer Biogen announced that it was halting two late-stage studies of the treatment after an interim analysis showed it was unlikely to work.

Other companies, though, are moving forward with experimental drugs of their own. Some target those familiar amyloid plaques and tau tangles, others look to inflammation and synapse regeneration, and still another mines young blood in search of therapeutic effect.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.